Skip to main content

Risk of Psychiatric Adverse Events among Montelukast Users

    Basic Details
    Date
    Type
    Publication
    Description

    There have been conflicting results from observational studies regarding the risk of psychiatric adverse events (PAEs) with montelukast use. The objective of this study was to determine if there are associations of depressive disorders, self-harm and suicide with use of montelukast compared to inhaled corticosteroid (ICS) use.

    This publication was also featured as a "Latest Research Summary" in The Journal Of Allergy And Clinical Immunology: In Practice as Risk of Psychiatric Adverse Events following Exposure to Montelukast.

    Author(s)

    Veronica V. Sansing-Foster, Nicole Haug, Andrew Mosholder, Noelle M. Cocoros, Marie Bradley, Yong Ma, Dinci Pennap, Elizabeth C. Dee, Sengwee Toh, Ella Pestine, Andrew B. Petrone, Ivone Kim, Jennifer G. Lyons, Efe Eworuke

    Corresponding Author

    Efe Eworuke; Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
    Email: efe.eworuke@fda.hhs.gov